135 related articles for article (PubMed ID: 9950286)
1. Surface activity and concentration dependent intestinal permeability in the rat.
Lindahl A; Persson B; Ungell AL; Lennernäs H
Pharm Res; 1999 Jan; 16(1):97-102. PubMed ID: 9950286
[TBL] [Abstract][Full Text] [Related]
2. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
3. Concentration- and region-dependent intestinal permeability of fluvastatin in the rat.
Lindahl A; Sandström R; Ungell AL; Lennernäs H
J Pharm Pharmacol; 1998 Jul; 50(7):737-44. PubMed ID: 9720622
[TBL] [Abstract][Full Text] [Related]
4. Jejunal permeability and hepatic extraction of fluvastatin in humans.
Lindahl A; Sandström R; Ungell AL; Abrahamsson B; Knutson TW; Knutson L; Lennernäs H
Clin Pharmacol Ther; 1996 Nov; 60(5):493-503. PubMed ID: 8941022
[TBL] [Abstract][Full Text] [Related]
5. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats.
Sandström R; Lennernäs H
Drug Metab Dispos; 1999 Aug; 27(8):951-5. PubMed ID: 10421625
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
7. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms.
Fagerholm U; Lindahl A; Lennernäs H
J Pharm Pharmacol; 1997 Jul; 49(7):687-90. PubMed ID: 9255712
[TBL] [Abstract][Full Text] [Related]
8. No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat.
Lindahl A; Frid S; Ungell AL; Lennernas H
AAPS PharmSci; 2000; 2(3):E26. PubMed ID: 11741242
[TBL] [Abstract][Full Text] [Related]
9. Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells.
Ohtawa M; Masuda N; Akasaka I; Nakashima A; Ochiai K; Moriyasu M
Br J Clin Pharmacol; 1999 Apr; 47(4):383-9. PubMed ID: 10233202
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Kim Y; Park K; Kang W
Biopharm Drug Dispos; 2010 Nov; 31(8-9):443-9. PubMed ID: 20809476
[TBL] [Abstract][Full Text] [Related]
11. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.
Tse FL; Smith HT; Ballard FH; Nicoletti J
Biopharm Drug Dispos; 1990; 11(6):519-31. PubMed ID: 2207302
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
13. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods.
Guillot F; Misslin P; Lemaire M
J Cardiovasc Pharmacol; 1993 Feb; 21(2):339-46. PubMed ID: 7679171
[TBL] [Abstract][Full Text] [Related]
15. Prediction of human absorption of a trioxane antimalarial drug (CDRI 99/411) using an in-house validated in situ single-pass intestinal perfusion model.
Wahajuddin ; Singh SP; Patel K; Pradhan T; Siddiqui HH; Singh SK
Arzneimittelforschung; 2011; 61(9):532-7. PubMed ID: 22029231
[TBL] [Abstract][Full Text] [Related]
16. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N
Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251
[TBL] [Abstract][Full Text] [Related]
20. Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models.
Xu YA; Fan G; Gao S; Hong Z
Drug Dev Ind Pharm; 2008 Feb; 34(2):164-70. PubMed ID: 18302035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
